Clinical trial / 2016
A single dose of resveratrol acutely increased cerebral vasodilator responsiveness in older adults with type 2 diabetes, with 75 mg showing maximum benefit.
In a balanced crossover trial, 36 adults with type 2 diabetes consumed single doses of synthetic trans-resveratrol (0, 75, 150, and 300 mg) at weekly intervals. CVR to a hypercapnic stimulus was assessed by transcranial Doppler ultrasound before and 45 minutes after treatment. Resveratrol increased CVR in the middle cerebral arteries, with mean within-individual changes from placebo of 13.8 ± 3.5% for 75 mg (P = 0.001), 8.9 ± 3.5% for 150 mg (P = 0.016), and 13.7 ± 3.3% for 300 mg (P < 0.001). Only the 75 mg dose significantly increased CVR in the posterior cerebral arteries (13.2 ± 4.5%, P = 0.016).
- Study type
- Double-blind, placebo-controlled, balanced crossover trial
- Who was studied
- 36 dementia-free, non-insulin dependent type 2 diabetes adults aged 49-78 years
- What was measured
- Cerebral vasodilator responsiveness (CVR) to hypercapnia in MCA and PCA
THE PAPER
Low dose resveratrol improves cerebrovascular function in type 2 diabetes mellitus.
Wong RH, Nealon RS, Scholey A, Howe PR. Nutr Metab Cardiovasc Dis, 2016.
This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.